Ashton LJ - Search Results

1

Second cancers and late mortality in Australian children treated by allogeneic HSCT for haematological malignancy.

Nelson AS, Ashton LJ, Vajdic CM, Le Marsney RE, Daniels B, Nivison-Smith I, Wilcox L, Dodds AJ, O'Brien TA; CAST study investigators. Nelson AS, et al. Among authors: ashton lj. Leukemia. 2015 Feb;29(2):441-7. doi: 10.1038/leu.2014.203. Epub 2014 Jun 25. Leukemia. 2015. PMID: 24962016

2

Second cancer risk in adults receiving autologous haematopoietic SCT for cancer: a population-based cohort study.

Bilmon IA, Ashton LJ, Le Marsney RE, Dodds AJ, O'Brien TA, Wilcox L, Nivison-Smith I, Daniels B, Vajdic CM; CAST study group. Bilmon IA, et al. Among authors: ashton lj. Bone Marrow Transplant. 2014 May;49(5):691-8. doi: 10.1038/bmt.2014.13. Epub 2014 Feb 17. Bone Marrow Transplant. 2014. PMID: 24535126

3

HIV infection in recipients of blood products from donors with known duration of infection.

Ashton LJ, Learmont J, Luo K, Wylie B, Stewart G, Kaldor JM. Ashton LJ, et al. Lancet. 1994 Sep 10;344(8924):718-20. doi: 10.1016/s0140-6736(94)92210-1. Lancet. 1994. PMID: 7915778

4

Predictors of progression in long-term nonprogressors. Australian Long-Term Nonprogressor Study Group.

Ashton LJ, Carr A, Cunningham PH, Roggensack M, McLean K, Law M, Robertson M, Cooper DA, Kaldor JM. Ashton LJ, et al. AIDS Res Hum Retroviruses. 1998 Jan 20;14(2):117-21. doi: 10.1089/aid.1998.14.117. AIDS Res Hum Retroviruses. 1998. PMID: 9462921

5

Effector HIV-specific cytotoxic T-lymphocyte activity in long-term nonprogressors: associations with viral replication and progression.

Keoshkerian E, Ashton LJ, Smith DG, Ziegler JB, Kaldor JM, Cooper DA, Stewart GJ, Ffrench RA. Keoshkerian E, et al. Among authors: ashton lj. J Med Virol. 2003 Dec;71(4):483-91. doi: 10.1002/jmv.10525. J Med Virol. 2003. PMID: 14556259

6

CCR5 promoter polymorphisms, CCR5 59029A and CCR5 59353C, are under represented in HIV-1-infected long-term non-progressors. The Australian Long-Term Non-Progressor Study Group.

Clegg AO, Ashton LJ, Biti RA, Badhwar P, Williamson P, Kaldor JM, Stewart GJ. Clegg AO, et al. Among authors: ashton lj. AIDS. 2000 Jan 28;14(2):103-8. doi: 10.1097/00002030-200001280-00004. AIDS. 2000. PMID: 10708279

7

Increased frequency of CCR-5 delta 32 heterozygotes among long-term non-progressors with HIV-1 infection. The Australian Long-Term Non-Progressor Study Group.

Stewart GJ, Ashton LJ, Biti RA, Ffrench RA, Bennetts BH, Newcombe NR, Benson EM, Carr A, Cooper DA, Kaldor JM. Stewart GJ, et al. Among authors: ashton lj. AIDS. 1997 Dec;11(15):1833-8. doi: 10.1097/00002030-199715000-00007. AIDS. 1997. PMID: 9412701

8

Immunologic and virologic status after 14 to 18 years of infection with an attenuated strain of HIV-1. A report from the Sydney Blood Bank Cohort.

Learmont JC, Geczy AF, Mills J, Ashton LJ, Raynes-Greenow CH, Garsia RJ, Dyer WB, McIntyre L, Oelrichs RB, Rhodes DI, Deacon NJ, Sullivan JS. Learmont JC, et al. Among authors: ashton lj. N Engl J Med. 1999 Jun 3;340(22):1715-22. doi: 10.1056/NEJM199906033402203. N Engl J Med. 1999. PMID: 10352163 Free article.

9

The historical development of epidemiological methods for studying HIV-1 disease progression.

Ashton LJ, Kaldor JM. Ashton LJ, et al. J Epidemiol Biostat. 2000;5(1):67-78. J Epidemiol Biostat. 2000. PMID: 10885873 No abstract available.

10

Heterozygosity for CCR5-Delta32 but not CCR2b-64I protects against certain intracellular pathogens.

Ashton LJ, Stewart GJ, Biti R, Law M, Cooper DA, Kaldor JM. Ashton LJ, et al. HIV Med. 2002 Apr;3(2):91-6. doi: 10.1046/j.1468-1293.2002.00106.x. HIV Med. 2002. PMID: 12010355 Free article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

58 results

Search Page

Filters